by jtcir-auto | Feb 19, 2025 | Press Releases
On-demand video webcast now available here AURORA, CO / ACCESS Newswire / February 19, 2025 / Exxel Pharma (“Exxel” or the “Company”), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal...
by jtcir-auto | Feb 3, 2025 | Press Releases
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in normal volunteers expected to commence enrollment in Q3/4 2025 with...
by jtcir-auto | Jan 31, 2025 | Press Releases
Live moderated video webcast on Wednesday, February 5th at 4:00 PM ET AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma (“Exxel” or the “Company”), a pharmaceutical company dedicated to developing novel therapeutics for the...
by jtcir-auto | May 1, 2024 | Press Releases
Live webcast with Soren Mogelsvang, PhD, Chief Executive Officer of Exxel Pharma, on Wednesday, May 8th at 12 PM ETAURORA, CO / ACCESSWIRE / May 1, 2024 / Exxel Pharma (“Exxel” or the “Company”), an early-stage pharma company working to develop...
by jtcir-auto | Jan 25, 2024 | Press Releases
Company advancing innovative, small molecule for treatment of refractory chronic cough where there are currently no FDA-approved therapies Lead program, EX937, initially targeting a $11B global market with potential to expand into multiple high-value indications...
by jtcir-auto | Oct 11, 2023 | Press Releases
Live moderated webcast with Soren Mogelsvang, PhD, Chief Executive Officer of Exxel Pharma Tuesday, October 24th at 3:00 PM ETAURORA, CO / ACCESSWIRE / October 11, 2023 / Exxel Pharma (“Exxel” or the “Company”), an early-stage pharma company...
